Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bispecific antibody, still with toxicity though, although pts had pretreatment with obinutumzumab to mitigate CRS. Response rate 35% in pts who received CAR-T therapy.
Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Author(s): Jennifer R. Brown1; Barbara Eichhorst2; Peter Hillmen3; Nicole Lamanna4; Susan M. O’Brien5; Constantine S. Tam6,7; Lugui Qiu8; Maciej Kaźmierczak9; Wojciech Jurczak10; Keshu Zhou11; Martin Šimkovič12,13; Jiri Mayer14; Amanda L. Gillespie-Twardy15; Alessandra Ferrajoli16; Peter S. Ganly17; Robert Weinkove18,19; Sebastian Grosicki20; Andrzej Mital21; Tadeusz Robak22; Anders Österborg23,24; Habte A. Yimer25; Tommi Salmi26; Megan (Der Yu) Wang26; Lina Fu26; Jessica Li26; Kenneth Wu26; Aileen Cohen26; Mazyar Shadman27,28
Source: Blood (2022) 140 (Supplement 2): LBA-6.
Dr. Maen Hussein's Thoughts
Two words: better and safer.
INTRODUCTION
CLL/SLL is usually characterized by consecutive relapses and response to therapy ultimately dictates survival. While ibrutinib, a first-generation Bruton tyrosine kinase inhibitor (BTKi), has become standard therapy, it has well-described off-target effects that can limit use. Compared with ibrutinib, zanubrutinib, a next-generation BTKi, provides improved BTK occupancy across disease-relevant tissues with greater kinase selectivity. In a randomized phase 3 study (ALPINE; NCT03734016), zanubrutinib was compared head-to-head with ibrutinib as treatment for R/R CLL/SLL. At predefined response analyses, zanubrutinib demonstrated superior overall response rate (ORR); data from the predefined final PFS analysis are reported here.
METHODS
Patients (pts) with R/R CLL/SLL who had received ≥1 prior therapy and had measurable disease were randomized 1:1 to receive zanubrutinib or ibrutinib until disease progression or unacceptable toxicity. Stratification was based on age, refractory status, geographical region, and del(17p)/TP53 mutation status. As the primary endpoint of ORR was superior with zanubrutinib, the key secondary efficacy endpoint of PFS was tested for noninferiority under hierarchical testing when 205 PFS events were observed. If PFS noninferiority between zanubrutinib and ibrutinib was demonstrated, superiority of zanubrutinib vs ibrutinib could be tested and claimed if the 2-sided P-value was <.04996. Other endpoints included overall survival (OS), ORR including PR with lymphocytosis (PR-L) or better, and safety parameters including atrial fibrillation/flutter.
RESULTS
Pts (N=652) from 15 countries were randomized to receive zanubrutinib (n=327) or ibrutinib (n=325). Demographic and disease characteristics were balanced between zanubrutinib and ibrutinib arms (age ≥65 yrs [61.5 vs 61.5%]; male [65.1 vs 71.4%]; unmutated IGHV [73.1 vs 73.5%]; del(17p) [13.8 vs 15.4%]; TP53 mutated without del(17p) [9.2 vs 7.7%]). Across the study population, median age was 67 and 68 yrs, respectively; in both arms, median prior lines of therapy was 1.
CONCLUSIONS
As ALPINE is the first study to demonstrate PFS superiority in a head-to-head comparison of BTK inhibitors, zanubrutinib has now proven superiority to ibrutinib in both ORR and PFS in pts with R/R CLL/SLL. Efficacy benefits with zanubrutinib were observed across all major subgroups, including high-risk pts. Zanubrutinib had a favorable safety profile compared with ibrutinib, with a lower rate of treatment discontinuation and fewer cardiac disorder events, including fewer cardiac events leading to death. These data suggest zanubrutinib is more efficacious and better tolerated than ibrutinib as treatment for R/R CLL/SLL.
Author Affiliations
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 2Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, Cologne, Germany 3St. James’s University Hospital, Leeds, United Kingdom 4Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 5Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 6Monash University, Melbourne, Australia 7The Alfred Hospital, Melbourne, Australia 8State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China 9Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland 10Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland 11Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China 124th Department of Internal Medicine – Hematology, University Hospital, Kralove, Czech Republic 13Faculty of Medicine, Charles University, Prague, Czech Republic 14Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic 15Blue Ridge Cancer Care, Roanoke, VA 16Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 17Department of Haematology, Christchurch Hospital, Christchurch, New Zealand 18Te Rerenga Ora Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, Wellington, New Zealand 19Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand 20Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland 21Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland 22Medical University of Lodz, Lodz, Poland 23Department of Hematology, Karolinska University Hospital, Stockholm, Sweden 24Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden 25Texas Oncology-Tyler/US Oncology Research, Tyler, TX 26BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA 27Fred Hutchinson Cancer Center, Seattle, WA 28Department of Medicine, University of Washington, Seattle, WARelated Articles
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse
This is not a randomized study, results though can not be ignored since ibrutinib is less toxic than many of the treatments used.
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Confirming that RR can be an alternative to R chemotherapy as a first line therapy in advanced stage follicular lymphoma.
CNS prophylaxis for diffuse large B-cell lymphoma
This is a nice historical accounting of this sometimes-challenging paradigm. No randomized, prospective trials exist to guide practice management. The question in clinic is often, when to use prophylaxis and when not? The CNS-IPI is the best scoring system validated in the Rituximab era. This did not account for double/triple hit genetics, ABC subtypes or sites of disease (gonads, >3 sites). A high score or any of these groups are generally those that benefit the most from CNS-prophylaxis. The field has moved away from IT-MTX therapy to HD-IV-MTX since most secondary CNSL is parenchymal in nature. Most relapses occur at months 6-9 so sooner is probably better in terms of timing.
